Nausea and Vomiting Clinical Trial
Official title:
A Study on Electroacupuncture Combined With Olanzapine-contained Four-drug Antiemetic Therapy for the Prevention of Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (ECO Study)
Verified date | December 2023 |
Source | Affiliated Hospital of Qinghai University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized controlled phase III trial aims to evaluate the use of electroacupuncture in combination with olanzapine-containing standard quadruple antiemetic drugs for the treatment of nausea and vomiting induced by highly emetogenic chemotherapy (HEC) in patients with breast cancer. Furthermore, it will analyze the relationship between single nucleotide polymorphism and electroacupuncture treatment for chemotherapy-induced nausea and vomiting.
Status | Recruiting |
Enrollment | 370 |
Est. completion date | December 31, 2026 |
Est. primary completion date | October 31, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Aged 18 years or older and aged 75 years or younger, of any nationality; 2. Eastern Cooperative Oncology Group performance status of 0-2; 3. Patients with breast cancer, with no restrictions on molecular typing; early-stage patients must not have undergone prior chemotherapy, while advanced-stage patients must be candidates for first-line chemotherapy and have declined neoadjuvant or adjuvant chemotherapy for over 3 months. All patients must receive highly emetogenic chemotherapy (HEC) based on anthracycline chemotherapy with cyclophosphamide (EC or AC) or carboplatin (AUC=4)/cisplatin; 4. Predicted life expectancy of =3 months; 5. Adequate bone marrow, kidney, and liver function; 6. Adequate contraception if premenopausal women; 7. Written informed consent by the patient before enrolment. Exclusion Criteria: 1. Patients already submitted to chemotherapy; 2. Is scheduled to receive any non-HEC on Day 1; 3. Is scheduled to receive any chemotherapy on days 2-4 after HEC; 4. Received or is scheduled to receive radiation therapy to the abdomen, pelvis, head and neck within 1 week prior to Day 1 or between Days 1 to 5 in cycle 1; 5. Has symptomatic primary or metastatic symptomatic central nervous system malignancy causing nausea and/or vomiting; 6. Have ongoing emesis or CTCAE grade 2 or greater nausea; 7. Significant medical or mental conditions; 8. Any allergies to study drug, antiemetics or dexamethasone; 9. Significantly abnormal laboratory values (platelets, coagulation indexes, absolute neutrophils, AST, ALT, bilirubin or creatinine); 10. Patients who are pregnant or breast-feeding; 11. Inflammatory skin reaction; 12. Has lymphedema in acupuncture stimulation area; 13. Patients who are afraid of electroacupuncture stimulation or allergic to stainless steel needles; 14. Received acupuncture treatments for any conditions less than 4 weeks before HEC; 15. Currently using drugs with antiemetic activity (e.g., 5-HT3 receptor antagonists, corticosteroids (except when used at physiological doses), dopamine receptor antagonists, minor tranquilizers, antihistamines, and benzodiazepines (except for nocturnal sedation)); 16. Patients with concomitant severe diseases or with a predisposition to emesis such as gastrointestinal obstruction, active peptic ulcer, and hypercalcemia and symptomatic brain metastasis; 17. Has a convulsive disorder requiring anticonvulsant treatment; 18. Patients administered thioridazine as a chronic antipsychotic medication (patients are allowed to receive prochlorperazine and other phenothiazines as a rescue antiemetic treatment); 19. Concurrent treatment with quinolone antibiotics; 20. Has a history of chronic alcoholism (determined by the investigator); 21. Known arrhythmias, uncontrolled congestive heart failure, or acute myocardial infarction within the past six months; 22. Has a history of uncontrolled diabetes (e.g., using insulin or oral hypoglycemic agents). |
Country | Name | City | State |
---|---|---|---|
China | Qinghai University Affiliated Hospital | Xining | Qinghai |
Lead Sponsor | Collaborator |
---|---|
Jiuda Zhao |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients with no nausea during the overall stage | The proportion of patients achieving no nausea is defined as patients who have a response of 0 on the visual-analogue scale for nausea during the overall stage (0 to 120 hours) after the initiation of chemotherapy. | 120 hours | |
Secondary | Proportion of patients with no nausea during the early stage | The proportion of patients achieving no nausea is defined as patients who have a response of 0 on the visual-analogue scale for nausea during the early stage (0 to 24 hours) after the initiation of chemotherapy | 24 hours | |
Secondary | Proportion of patients with no nausea during the delayed stage | The proportion of patients achieving no nausea is defined as patients who have a response of 0 on the visual-analogue scale for nausea during the later stage (25 to 120 hours) after the initiation of chemotherapy | 96 hours | |
Secondary | The relationship between single nucleotide polymorphism genotypes and the proportion of patients with no nausea | The single nucleotide polymorphism (SNP) genotypes will be analyzed by detecting different bases (A, T, C, and G) in peripheral blood DNA. The proportion of patients with different SNP genotypes will be analyzed. The proportion of patients achieving no nausea is defined as patients who score 0 on the nausea visual analogue scale during the entire period (0 to 120 hours) following the initiation of chemotherapy. We will analyze the relationship between the proportion of patients with different SNP genotypes and the proportion of patients with no nausea | 120 hours | |
Secondary | The proportion of patients achieving total control in the overall stage, the early stage (0 to 24 hours), and the delayed stage (25 to 120 hours). | The proportion of patients achieving overall stage, early stage and delayed stage total control is defined as patients who have no vomiting/retching or rescue medications, and no nausea, specifically indicated by a nausea visual analog scale score of 0 during 0 to 120 hours, 0 to 24 hours, and 25 to 120 hours after the initiation of chemotherapy, respectively | 120 hours | |
Secondary | The proportion of patients achieving complete protection in the overall stage, the early stage (0 to 24 hours), and the delayed stage (25 to 120 hours) | The proportion of patients achieving overall stage, early stage and delayed stage complete protection is defined as patients who have no vomiting/retching or rescue medications, and no significant nausea, specifically indicated by a nausea visual analog scale score of less than 25 mm during 0 to 120 hours, 0 to 24 hours, and 25 to 120 hours after the initiation of chemotherapy, respectively | 120 hours | |
Secondary | The proportion of no significant nausea in the overall stage, the early stage (0 to 24 hours), and the delayed stage (25 to 120 hours) | The proportion of patients achieving overall stage, early stage and delayed stage no significant nausea is defined as patients who have no significant nausea, specifically indicated by a nausea visual analog scale score of less than 25 mm during 0 to 120 hours, 0 to 24 hours, and 25 to 120 hours after the initiation of chemotherapy, respectively | 120 hours | |
Secondary | The proportion of no nausea (visual analog scale score equal to 5) in the overall stage, the early stage (0 to 24 hours), and the delayed stage (25 to 120 hours) | The proportion of patients achieving overall stage, early stage and delayed stage no nausea (visual analog scale score equal to 5) is defined as patients who have no nausea (visual analog scale score equal to 5), specifically indicated by a nausea visual analog scale score equal to 5 mm during 0 to 120 hours, 0 to 24 hours, and 25 to 120 hours after the initiation of chemotherapy, respectively | 120 hours | |
Secondary | The proportion of patients achieving complete response in the overall stage, the early stage (0 to 24 hours), and the delayed stage (25 to 120 hours) | The proportion of patients achieving overall stage complete response is defined as patients who have no vomiting/retching or rescue medications during 0 to 120 hours, 0 to 24 hours, and 25 to 120 hours after the initiation of chemotherapy, respectively | 120 hours | |
Secondary | Quality of life in the overall stage | EuroQol Five Dimensions Questionnaire (EQ-5D) is a standardized instrument used for assessing an individual's health-related quality of life. It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has three levels that describe the person's level of functioning or well-being in that specific area. Additionally, EQ-5D includes a visual analog scale where individuals rate their overall health on a scale from 0 (worst imaginable health) to 100 (best imaginable health) | 120 hours | |
Secondary | Insomnia | The proportion of patients with insomnia evaluated by Common Terminology Criteria for adverse events Version 5.0 during 0 to120 hours after the initiation of chemotherapy | 120 hours | |
Secondary | Fatigue | The proportion of patients with fatigue evaluated by Common Terminology Criteria for adverse events Version 5.0 during 0 to120 hours after the initiation of chemotherapy | 120 hours | |
Secondary | Constipation | The proportion of patients with constipation evaluated by Common Terminology Criteria for adverse events Version 4.0 during 0 to120 hours after the initiation of chemotherapy | 120 hours | |
Secondary | The side effects of electroacupuncture treatment | The proportion of side effects related to electroacupuncture treatment in patients evaluated by Common Terminology Criteria for adverse events Version 5.0 during 0 to120 hours after the initiation of chemotherapy | 120 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05016180 -
Effect of Ultrasound-guided Transversus Abdominis Plane Block After Laparoscopic Bariatric Surgery
|
Phase 2 | |
Withdrawn |
NCT00891761 -
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
|
Phase 3 | |
Terminated |
NCT00903396 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
|
Phase 2 | |
Completed |
NCT05533281 -
Efficacy of Three Antiemetics in Preventing Nausea and Vomiting
|
Phase 4 | |
Recruiting |
NCT01696734 -
Domperidone in Treating Patients With Gastrointestinal Disorders
|
Phase 3 | |
Completed |
NCT00293384 -
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
|
N/A | |
Completed |
NCT00006348 -
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
|
Phase 3 | |
Completed |
NCT00004895 -
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
|
Phase 2 | |
Completed |
NCT00003817 -
Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy
|
Phase 2 | |
Active, not recruiting |
NCT06045364 -
Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation
|
Phase 1/Phase 2 | |
Completed |
NCT00978185 -
Acupressure Wristbands or Standard Care in Controlling Nausea Caused by Chemotherapy
|
Phase 3 | |
Completed |
NCT00064272 -
UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
|
Phase 2 | |
Completed |
NCT00003213 -
Drugs to Reduce the Side Effects of Chemotherapy
|
Phase 3 | |
Recruiting |
NCT05690802 -
The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV
|
N/A | |
Recruiting |
NCT06314906 -
Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
|
Phase 3 | |
Completed |
NCT00590317 -
Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department
|
Phase 2 | |
Completed |
NCT03185156 -
The Preventive Effects of Sub Hypnotic Dose of Propofol for Nausea and Vomiting Induced by Hemabate
|
Phase 4 | |
Not yet recruiting |
NCT06382012 -
Antiemetic Fosaprepitant To Remedy Nausea and Vomiting
|
Phase 2/Phase 3 | |
Terminated |
NCT01275664 -
Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
|
N/A | |
Completed |
NCT01590147 -
Supportive Intervention Programs Study
|
N/A |